Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.08. | Biotech Destiny Pharma Tips Into Insolvency in Cash Crisis | 3 | BNN Bloomberg | ||
20.08. | JP Jenkins Ltd: Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula | 309 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative... ► Artikel lesen | |
14.08. | JP Jenkins Ltd: Destiny Pharma initiates research to explore XF drug potential for CF | 259 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma initiates research to explore XF drug potential for CF 14-Aug-2024 / 11:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
13.08. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.08.2024 | 411 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.08.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.08.2024ISIN NameCA44053J4090 HORIZON... ► Artikel lesen | |
13.08. | JP Jenkins Ltd: Destiny Pharma plc shares now trading on JP Jenkins | 194 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma plc shares now trading on JP Jenkins 13-Aug-2024 / 09:36 GMT/BST
The issuer is solely responsible for the content of this announcement.
13th Aug... ► Artikel lesen | |
13.08. | AIM - Cancellation - Destiny Pharma plc | 1 | RNS | ||
13.08. | XFRA D89: AUSSETZUNG/SUSPENSION | 152 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDESTINY PHARMA PLC... ► Artikel lesen | |
12.08. | Destiny Pharma PLC - Last Day of Dealings on AIM | - | RNS | ||
06.08. | FTSE Russell - Destiny Pharma: Constituent Deletion - Changes in FTSE UK Index Series | 2 | RNS | ||
05.08. | Small Cap Stocks: Destiny Pharma, Tower Resources, UK Oil & Gas | 2 | The Armchair Trader | ||
05.08. | Destiny Pharma reports positive findings from XF-73 study | 1 | Sharecast | ||
05.08. | Destiny Pharma PLC - Director/PDMR Shareholding | 1 | RNS | ||
05.08. | Destiny Pharma shares fall amid XF-73 fending off MRSA in wounds | 1 | Alliance News | ||
05.08. | Destiny Pharma PLC - XF-73 prevents bacterial invasion of bloodstream | 1 | RNS | ||
31.07. | Destiny Pharma PLC - Result of GM and Cancellation of Trading on AIM | 1 | RNS | ||
22.07. | Small Cap Stocks: Future Metals, Wishbone Gold, Destiny Pharma | 4 | The Armchair Trader | ||
22.07. | Destiny Pharma PLC - Treatment of XF-73 Nasal reduces antibiotic use | 1 | RNS | ||
15.07. | Small Cap Stocks: Gfinity, Caspian Sunrise, Destiny Pharma | 2 | The Armchair Trader | ||
15.07. | London markets weak at midday, Burberry, Destiny Pharma smashed | 4 | Shares | ||
15.07. | AIM WINNERS & LOSERS: Destiny Pharma falls on plans to go private | 1 | Alliance News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CORE ONE LABS | 0,079 | 0,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
SKINBIOTHERAPEUTICS | 0,180 | +1,69 % | IN BRIEF: SkinBioTherapeutics boosts financial 2025 turnover forecast | ||
QIAGEN | 39,730 | +1,74 % | Biotech Report: Evotec ziehen an, Qiagen behauptet, US-Sektor unter Druck | (shareribs.com) Frankfurt / New York 29.10.2024 - Die Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Für Evotec ging es nach oben, Qiagen schlossen flach. An der Wall Street gibt der... ► Artikel lesen | |
ADMA BIOLOGICS | 19,245 | +18,00 % | ADMA Biologics jumps as KPMG becomes new auditor | ||
EVOTEC | 7,145 | +0,78 % | Evotec - Das ist die Wende für Anleger!: Reboundchance dank Deal mit Bristol Myers | © Foto: SymbolbildDie Evotec-Aktie gibt gerade ordentlich Gas: Nach einem tiefen Fall von 70 % seit Jahresbeginn hat das Unternehmen nun durch eine Partnerschaft mit dem Pharmariesen Bristol Myers Squibb... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,120 | +3,08 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,68 | -0,08 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
BIONTECH | 102,40 | -0,87 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 9,160 | +22,30 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
NUVALENT | 88,46 | -0,03 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results | Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET / 2:30 p.m. CEST
$658.0 million in cash, cash equivalents and marketable... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,435 | +1,82 % | Recursion Pharmaceuticals-Direktor Blake Borgeson verkauft Aktien im Wert von 76.926 US-Dollar | ||
SUMMIT THERAPEUTICS | 18,860 | +1,45 % | Summit Therapeutics Aktie: Bleiben Sie wachsam! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnete am 26. Oktober 2024 einen bemerkenswerten Kursanstieg von 9,25% auf 21,26 USD. Dieser Aufschwung erfolgt trotz einer herausfordernden... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 42,100 | -0,38 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
VERA THERAPEUTICS | 43,500 | +7,73 % | Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 | Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN... ► Artikel lesen |